• June 3-6, 2024
  • San Diego Convention Center, California

Sessions

Loading

Tharimmune, Inc.

Monday, June 03, 2024
CP
Multiple Therapeutics
Tharimmune (nasdaq: THAR) is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases. The Company's lead clinical-stage asset, TH104 is known to suppress chronic, debilitating pruritis or “uncontrollable itching” in PBC, a rare and orphan liver disease with no known cure. The Company’s early-stage IO pipeline includes novel multi-specific antibodies targeting unique epitopes with novel mechanisms of action against well-known, validated targets (PD-1, HER2, HER3) in multiple solid tumors. Tharimmune has a license agreement with OmniAb, Inc. to access the company’s antibody discovery technology platform against specified targets.
Tharimmune, Inc.
Company Website: https://tharimmune.com/
Lead Product in Development: TH104 is embedded with nalmefene onto a proprietary transdermal buccal film which easily adheres to the inside of the mouth. This endows TH104 with key features making it an ideal product candidate for multiple liver-related and other pruritogenic inflammatory conditions. The molecule has a dual mechanism of action affecting both the µ-opioid and kappa opioid receptors. These opioid receptors when stimulated and/or inhibited by the body's natural ligands have been known to be involved in the body's itch circuitry.
Number Of Unlicensed Products (For Which You Are Seeking Partners): Multiple

Exchange

NASDAQ

Ticker

THAR

Company HQ City

Bridgewater

Company HQ State

New Jersey

Company HQ Country

United States

CEO/Top Company Official

Randy Milby

Development Phase of Primary Product

Phase II
Back to Session List

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS